ACR ASX · Health Care

ACRUX Ltd

Announcements, last 12 months: 71
Price sensitive, last 12 months: 20

Latest announcements

Released	Headline	Actions
23 Oct 2026, 8:20 AM	Notice of Annual General Meeting/Proxy Form
19 Oct 2026, 3:00 PM	Application for quotation of securities - ACR
19 Oct 2026, 9:39 AM	Quarterly Activities/Appendix 4C Cash Flow Report Price sensitive
12 Oct 2026, 9:30 AM	FDA clears regulatory pathway for Female Testosterone MDTS Price sensitive
9 Oct 2026, 8:51 AM	Webinar, Monday 12 October 2026 - Female Testosterone MDTS
2 Oct 2026, 8:22 AM	Acrux has received $1.977m RDTI rebate for FY26 Price sensitive
24 Sep 2026, 8:29 AM	Application for quotation of securities - ACR
14 Sep 2026, 9:21 AM	AGM date, closing date for director nominations
14 Sep 2026, 9:18 AM	Appendix 3Y Brooke
14 Sep 2026, 9:17 AM	Application for quotation of securities - ACR

Sign in to see all ACR announcements.

Guidance history

25 Feb 2025	Acrux expects to generate additional revenue from the recent approval of Efinaconazole Topical Solution and the planned launches of Dapsone 7.5% Gel and Nitroglycerin Rectal Ointment in FY25.
30 Jan 2025	Acrux expects increases in customer revenue to be reported in future periods due to the new commercial product activity and the company's other revenue-generating products from its topical generic portfolio.

Most followed in Health Care

PME Pro Medicus Ltd
AHC Austco Healthcare Ltd
CSL CSL Ltd
RMD Resmed Inc
TLX TELIX Pharmaceuticals Ltd
CGS Cogstate Ltd
ALC Alcidion Group Ltd
CSX Cleanspace Holdings Ltd

Follow ACR to get its announcements emailed to you, with AI summaries, the full announcement and guidance history, and its most significant announcements.